Dual targeting of tumoral cells and immune microenvironment by blocking the IL-33/IL1RL1 pathway

Abstract Leukemia stem cells (LSCs) are a small yet powerful subset of leukemic cells that possess the ability to self-renew and have a long-term tumorigenic capacity, playing a crucial role in both leukemia development and therapy resistance. These LSCs are influenced by external and internal facto...

Full description

Saved in:
Bibliographic Details
Main Authors: Denggang Fu, Hua Jiang, Alan Long, Ella Harris, Hongfen Guo, Maegan L. Capitano, John Wrangle, Joshua R. Faust, Anilkumar Gopalakrishnapillai, Santhosh Kumar Pasupuleti, Baskar Ramdas, Reuben Kapur, Sonali P. Barwe, Nai-Kong V. Cheung, Sophie Paczesny
Format: Article
Language:English
Published: Nature Portfolio 2025-07-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-025-61567-7
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849332525924614144
author Denggang Fu
Hua Jiang
Alan Long
Ella Harris
Hongfen Guo
Maegan L. Capitano
John Wrangle
Joshua R. Faust
Anilkumar Gopalakrishnapillai
Santhosh Kumar Pasupuleti
Baskar Ramdas
Reuben Kapur
Sonali P. Barwe
Nai-Kong V. Cheung
Sophie Paczesny
author_facet Denggang Fu
Hua Jiang
Alan Long
Ella Harris
Hongfen Guo
Maegan L. Capitano
John Wrangle
Joshua R. Faust
Anilkumar Gopalakrishnapillai
Santhosh Kumar Pasupuleti
Baskar Ramdas
Reuben Kapur
Sonali P. Barwe
Nai-Kong V. Cheung
Sophie Paczesny
author_sort Denggang Fu
collection DOAJ
description Abstract Leukemia stem cells (LSCs) are a small yet powerful subset of leukemic cells that possess the ability to self-renew and have a long-term tumorigenic capacity, playing a crucial role in both leukemia development and therapy resistance. These LSCs are influenced by external and internal factors within the bone marrow niche. By delving into the intricate interplay between LSCs and their immune environment, we can pave the way for innovative immunotherapies that target both the malignant stem cells and the suppressive immune microenvironment, addressing both the “seed” and the “soil” simultaneously. Through the analysis of public datasets and patient samples, we show that elevated IL1RL1 expression correlates with poor prognosis and therapy resistance in acute myeloid leukemia (AML). At the core of this process, stem cell leukemogenesis initiation and maintenance signals are driven by a stress-induced IL-33/IL1RL1 autocrine loop. This LSC-induced IL-33/IL1RL1 signaling fosters an immune regulatory microenvironment. Therefore, IL1RL1 emerges as a promising therapeutic target, with IL1RL1-specific T cell-engaging bispecific antibodies holding great potential as cutting-edge immunotherapeutics for AML.
format Article
id doaj-art-6687d4cd6f9b429e9f411746c11278fc
institution Kabale University
issn 2041-1723
language English
publishDate 2025-07-01
publisher Nature Portfolio
record_format Article
series Nature Communications
spelling doaj-art-6687d4cd6f9b429e9f411746c11278fc2025-08-20T03:46:11ZengNature PortfolioNature Communications2041-17232025-07-0116112110.1038/s41467-025-61567-7Dual targeting of tumoral cells and immune microenvironment by blocking the IL-33/IL1RL1 pathwayDenggang Fu0Hua Jiang1Alan Long2Ella Harris3Hongfen Guo4Maegan L. Capitano5John Wrangle6Joshua R. Faust7Anilkumar Gopalakrishnapillai8Santhosh Kumar Pasupuleti9Baskar Ramdas10Reuben Kapur11Sonali P. Barwe12Nai-Kong V. Cheung13Sophie Paczesny14Department of Microbiology and Immunology and Pediatrics, Medical University of South CarolinaDepartment of Microbiology and Immunology and Pediatrics, Medical University of South CarolinaDepartment of Pediatrics, Memorial Sloan Kettering Cancer CenterDepartment of Microbiology and Immunology and Pediatrics, Medical University of South CarolinaDepartment of Pediatrics, Memorial Sloan Kettering Cancer CenterDepartment of Pediatrics, Indiana University School of MedicineDepartment of Microbiology and Immunology and Medicine, Medical University of South CarolinaNemours Children’s Hospital, Lisa Dean Moseley Foundation Institute of Cancer and Blood DisordersNemours Children’s Hospital, Lisa Dean Moseley Foundation Institute of Cancer and Blood DisordersDepartment of Pediatrics, Indiana University School of MedicineDepartment of Pediatrics, Indiana University School of MedicineDepartment of Pediatrics, Indiana University School of MedicineNemours Children’s Hospital, Lisa Dean Moseley Foundation Institute of Cancer and Blood DisordersDepartment of Pediatrics, Memorial Sloan Kettering Cancer CenterDepartment of Microbiology and Immunology and Pediatrics, Medical University of South CarolinaAbstract Leukemia stem cells (LSCs) are a small yet powerful subset of leukemic cells that possess the ability to self-renew and have a long-term tumorigenic capacity, playing a crucial role in both leukemia development and therapy resistance. These LSCs are influenced by external and internal factors within the bone marrow niche. By delving into the intricate interplay between LSCs and their immune environment, we can pave the way for innovative immunotherapies that target both the malignant stem cells and the suppressive immune microenvironment, addressing both the “seed” and the “soil” simultaneously. Through the analysis of public datasets and patient samples, we show that elevated IL1RL1 expression correlates with poor prognosis and therapy resistance in acute myeloid leukemia (AML). At the core of this process, stem cell leukemogenesis initiation and maintenance signals are driven by a stress-induced IL-33/IL1RL1 autocrine loop. This LSC-induced IL-33/IL1RL1 signaling fosters an immune regulatory microenvironment. Therefore, IL1RL1 emerges as a promising therapeutic target, with IL1RL1-specific T cell-engaging bispecific antibodies holding great potential as cutting-edge immunotherapeutics for AML.https://doi.org/10.1038/s41467-025-61567-7
spellingShingle Denggang Fu
Hua Jiang
Alan Long
Ella Harris
Hongfen Guo
Maegan L. Capitano
John Wrangle
Joshua R. Faust
Anilkumar Gopalakrishnapillai
Santhosh Kumar Pasupuleti
Baskar Ramdas
Reuben Kapur
Sonali P. Barwe
Nai-Kong V. Cheung
Sophie Paczesny
Dual targeting of tumoral cells and immune microenvironment by blocking the IL-33/IL1RL1 pathway
Nature Communications
title Dual targeting of tumoral cells and immune microenvironment by blocking the IL-33/IL1RL1 pathway
title_full Dual targeting of tumoral cells and immune microenvironment by blocking the IL-33/IL1RL1 pathway
title_fullStr Dual targeting of tumoral cells and immune microenvironment by blocking the IL-33/IL1RL1 pathway
title_full_unstemmed Dual targeting of tumoral cells and immune microenvironment by blocking the IL-33/IL1RL1 pathway
title_short Dual targeting of tumoral cells and immune microenvironment by blocking the IL-33/IL1RL1 pathway
title_sort dual targeting of tumoral cells and immune microenvironment by blocking the il 33 il1rl1 pathway
url https://doi.org/10.1038/s41467-025-61567-7
work_keys_str_mv AT denggangfu dualtargetingoftumoralcellsandimmunemicroenvironmentbyblockingtheil33il1rl1pathway
AT huajiang dualtargetingoftumoralcellsandimmunemicroenvironmentbyblockingtheil33il1rl1pathway
AT alanlong dualtargetingoftumoralcellsandimmunemicroenvironmentbyblockingtheil33il1rl1pathway
AT ellaharris dualtargetingoftumoralcellsandimmunemicroenvironmentbyblockingtheil33il1rl1pathway
AT hongfenguo dualtargetingoftumoralcellsandimmunemicroenvironmentbyblockingtheil33il1rl1pathway
AT maeganlcapitano dualtargetingoftumoralcellsandimmunemicroenvironmentbyblockingtheil33il1rl1pathway
AT johnwrangle dualtargetingoftumoralcellsandimmunemicroenvironmentbyblockingtheil33il1rl1pathway
AT joshuarfaust dualtargetingoftumoralcellsandimmunemicroenvironmentbyblockingtheil33il1rl1pathway
AT anilkumargopalakrishnapillai dualtargetingoftumoralcellsandimmunemicroenvironmentbyblockingtheil33il1rl1pathway
AT santhoshkumarpasupuleti dualtargetingoftumoralcellsandimmunemicroenvironmentbyblockingtheil33il1rl1pathway
AT baskarramdas dualtargetingoftumoralcellsandimmunemicroenvironmentbyblockingtheil33il1rl1pathway
AT reubenkapur dualtargetingoftumoralcellsandimmunemicroenvironmentbyblockingtheil33il1rl1pathway
AT sonalipbarwe dualtargetingoftumoralcellsandimmunemicroenvironmentbyblockingtheil33il1rl1pathway
AT naikongvcheung dualtargetingoftumoralcellsandimmunemicroenvironmentbyblockingtheil33il1rl1pathway
AT sophiepaczesny dualtargetingoftumoralcellsandimmunemicroenvironmentbyblockingtheil33il1rl1pathway